The stock of Epizyme Inc (NASDAQ:EPZM) is a huge mover today! About 185,627 shares traded hands. Epizyme Inc (NASDAQ:EPZM) has declined 28.63% since April 4, 2016 and is downtrending. It has underperformed by 29.72% the S&P500.
The move comes after 9 months positive chart setup for the $563.63M company. It was reported on Nov, 4 by Barchart.com. We have $14.79 PT which if reached, will make NASDAQ:EPZM worth $293.09 million more.
Analysts await Epizyme Inc (NASDAQ:EPZM) to report earnings on November, 14. They expect $-0.56 EPS, 0.00% or $0.00 from last year’s $-0.56 per share. After $-0.49 actual EPS reported by Epizyme Inc for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Epizyme Inc (NASDAQ:EPZM) Ratings Coverage
Out of 7 analysts covering Epizyme (NASDAQ:EPZM), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Epizyme has been the topic of 9 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Mizuho with “Buy” on Thursday, August 6. On Tuesday, August 25 the stock rating was downgraded by Zacks to “Buy”. The stock of Epizyme Inc (NASDAQ:EPZM) has “Buy” rating given on Tuesday, April 5 by Citigroup. The firm has “Buy” rating given on Monday, March 14 by H.C. Wainwright. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, September 28. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm earned “Buy” rating on Tuesday, May 10 by Mizuho.
According to Zacks Investment Research, “Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.64 in Q2 2016. Its down 1.17, from 2.81 in 2016Q1. The ratio dived, as 8 funds sold all Epizyme Inc shares owned while 20 reduced positions. 14 funds bought stakes while 32 increased positions. They now own 45.74 million shares or 3.00% more from 44.40 million shares in 2016Q1.
Loring Wolcott And Coolidge Fiduciary Advsrs Limited Liability Partnership Ma has invested 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Oxford Asset Mgmt has 0.06% invested in the company for 133,351 shares. The New York-based Baker Bros Advsr L P has invested 0.02% in Epizyme Inc (NASDAQ:EPZM). The New York-based Morgan Stanley has invested 0% in Epizyme Inc (NASDAQ:EPZM). New York State Common Retirement Fund has 37,800 shares for 0% of their US portfolio. Metropolitan Life Ins Ny has 31,085 shares for 0% of their US portfolio. Citigroup has 9,545 shares for 0% of their US portfolio. Bank Of New York Mellon Corporation reported 169,352 shares or 0% of all its holdings. Cqs Cayman L P holds 0.57% or 635,000 shares in its portfolio. Geode Capital Ltd Llc reported 301,224 shares or 0% of all its holdings. The New York-based Tocqueville Asset Mngmt Ltd Partnership has invested 0% in Epizyme Inc (NASDAQ:EPZM). Bnp Paribas Arbitrage last reported 1,634 shares in the company. Us State Bank De reported 2,000 shares or 0% of all its holdings. Iguana Ltd Llc holds 0.83% or 200,000 shares in its portfolio. California State Teachers Retirement Sys holds 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM) for 84,441 shares.
Insider Transactions: Since May 9, 2016, the stock had 0 buys, and 8 sales for $141,349 net activity. Shares for $9,914 were sold by Singer Andrew E.. 4,000 shares were sold by Copeland Robert A, worth $41,492.
More notable recent Epizyme Inc (NASDAQ:EPZM) news were published by: Fool.com which released: “Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today” on January 07, 2016, also Businesswire.com with their article: “Epizyme Announces Pricing of Public Offering of Common Stock” published on January 07, 2016, Businesswire.com published: “Epizyme Announces Closing of Public Offering of Common Stock” on January 12, 2016. More interesting news about Epizyme Inc (NASDAQ:EPZM) were released by: Businesswire.com and their article: “Epizyme Announces Proposed Public Offering of Common Stock” published on January 05, 2016 as well as Businesswire.com‘s news article titled: “Epizyme Announces FDA Acceptance of Investigational New Drug Application for …” with publication date: December 28, 2015.
EPZM Company Profile
Epizyme, Inc., incorporated on November 1, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. The Firm develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. The Firm develops small molecule inhibitors of other chromatin modifying proteins, or CMPs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.